Monday, September 16, 2013

KV Pharmaceuticals emerges from bankruptcy


ST. LOUIS -- KV Pharmaceuticals Co., maker of a much-debated drug to prevent preterm birth, said Monday it has emerged from chapter 11 bankruptcy with $375 million in credit and shares.
The company said it has secured a new $100 million credit facility and $275 million rights offering and direct purchase of new common shares. The company's recapitalization was led by investors including Capital Ventures International, Greywolf Capital, Kingdon Capital and Deutsche Bank.
The specialty pharmaceutical company focuses on women's health, marketingproducts for hot flashes, yeast infection and other conditions. The company has been criticized for the pricing of its leading drug Makena, which is approved to prevent preterm birth in women who've already had one premature infant and now are pregnant again. KV Pharmaceuticals sells the drug for $690 per weekly injection, though it can also be purchased in generic form for $10 to $20 a dose from compounding pharmacies that mix customized medications.
continue to read here

No comments: